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Abstract
Background: Listeria monocytogenes is the third most frequent cause of bacterial meningitis. The aim of this study
is to know the incidence and risk factors associated with development of acute community-acquired Lm
meningitis in adult patients and to evaluate the clinical features, management, and outcome in this prospective
case series.
Methods: A descriptive, prospective, and multicentric study carried out in 9 hospitals in the Spanish Network for
Research in Infectious Diseases (REIPI) over a 39-month period. All adults patients admitted to the participating
hospitals with the diagnosis of acute community-acquired bacterial meningitis (Ac-ABM) were included in this
study. All these cases were diagnosed on the basis of a compatible clinical picture and a positive cerebrospinal
fluid (CSF) culture or blood culture. The patients were followed up until death or discharge from hospital.
Results: Two hundred and seventy-eight patients with Ac-ABM were included. Forty-six episodes of Lm meningitis
were identified in 46 adult patients. In the multivariate analysis only age (OR 1.026; 95% CI 1.00-1.05; p = 0.042),
immunosupression (OR 2.520; 95% CI 1.05-6.00; p = 0.037), and CSF/blood glucose ratio (OR 39.42; 95% CI 4.01-
387.50; p = 0.002) were independently associated with a Lm meningitis. The classic triad of fever, neck stiffness and
altered mental status was present in 21 (49%) patients, 32% had focal neurological findings at presentation, 12%
presented cerebellum dysfunction, and 9% had seizures. Twenty-nine (68%) patients were immunocompromised.
Empirical antimicrobial therapy was intravenous ampicillin for 34 (79%) of 43 patients, in 11 (32%) of them
associated to aminoglycosides. Definitive ampicillin plus gentamicin therapy was significantly associated with
unfavourable outcome (67% vs 28%; p = 0.024) and a higher mortality (67% vs 32%; p = 0.040).The mortality rate
was 28% (12 of 43 patients) and 5 of 31 (16.1%) surviving patients developed adverse clinical outcome.
Conclusions: Elderly or immunocompromised patients, and a higher CSF/blood glucose ratio in patients with
Ac-ABM must alert clinicians about Lm aetiology. Furthermore, we observed a high incidence of acute community-
acquired Lm meningitis in adults and the addition of aminoglycosides to treatment should be avoid in order to
improve the patients’ outcome. Nevertheless, despite developments in intensive care and antimicrobial therapy,
this entity is still a serious disease that carries high morbidity and mortality rates.
Background
Listeria monocytogenes (Lm) is a Gram-positive, faculta-
tive anaerobic bacterium that primarily causes sepsis and
meningitis [1] in either immunocompromised or immu-
nocompetent hosts [2,3]. As a foodborne pathogen, it has
emerged as a significant public health problem and has
caused several epidemics in the United States and Eur-
ope. Community-acquired Lm meningitis is a serious and
life-threatening disease. The estimated incidence is 0.2
cases per 100.000 adults per year in developed countries
[1]. Lm is the third most frequent cause of community-
acquired bacterial meningitis, after Streptococcus pneu-
moniae and Neisseria meningitidis aetiologies, due to the
vaccine-related decline in Haemophilus influenzae type b
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promised patients, newborns, and elderly individuals [4],
although previously healthy adults can be affected as well
[5]. Even with appropriate antibiotic therapy, this entity
has a high morbidity and mortality (24%-62%) [2-4,6-8].
In this report, we set out to study the incidence and
risk factors associated with development of acute com-
munity-acquired Lm meningitis in adult patients and to
evaluate the clinical features, management, and outcome
in this prospective case series.
Methods
This is a prospective multicenter observational study
carried out in 9 Spanish hospitals. All these hospitals
are large institutions with teaching accreditation. The
study was conducted over a 39-month period. All
patients over 14 years old admitted to the participating
hospitals with the diagnosis of acute community-
acquired bacterial meningitis (Ac-ABM) were included
in this study. The Ethical committees approved the
study and did not require informed consent from the
patient.
One investigator at each hospital prospectively
recorded variables of all Ac-ABM in a previously
designed database collecting data on patients’ demogra-
phy, clinical antecedents, symptoms and signs at admis-
sion, laboratory findings, clinical course, treatment, and
outcome. Episodes of Ac-ABM were diagnosed on the
basis of compatible clinical picture and at least 1 of the
following cerebrospinal fluid( C S F )f i n d i n g s :C S Fp o l y -
morphonuclear (PMN) pleocytosis [white blood cells
(WBC) count >10/μl, 90% neutrophils, hipoglycorrachia
<40 mg/dL or CSF/blood glucose ratio <40%, increased
protein level >1 g/L, a positive CSF Gram’s stain or cul-
ture, and/or positive blood cultures. When the CSF
Gram’s stain and blood and CSF cultures were negative,
meningitis of unknown aetiology was recorded. Menin-
gitis was considered to be community-acquired when-
ever a patient had not been previously treated in a
hospital. If the patient had been previously admitted,
Ac-ABM was diagnosed whenever the onset of the dis-
ease occurred 2 weeks after discharge or after 4 weeks if
the patient had undergone surgery [9].
Lm meningitis was diagnosed in those patients with
Ac-ABM in whom Lm was isolated in the CSF, blood
culture, or both. Serotyping Lm was done using specific
antisera, as described elsewhere [10].
Patients were considered immunocompromised if they
were receiving immunosuppressive therapy and/or had
haematological and solid malignancy, connective tissue
disease, diabetes mellitus, alcoholism, asplenia, liver cir-
rhosis, end-stage renal disease, or HIV infection [11].
Patients were considered elderly when they were 60
years or older.
The classic triad was defined when fever, neck stiff-
ness and change in mental status were present. Hypona-
tremia was defined as a plasma sodium concentration
<135 mmol/L [12]. Focal neurological deficit was diag-
nosed when aphasia, monoparesis, hemiparesis or cra-
nial nerve palsies were present at admission or during
hospitalisation. Cerebellum dysfunction was diagnosed
in patients with nystagmus, dysarthria, or limb and gait
ataxia.
Time to admission was defined as the appearance of
symptoms to admission to the hospital. Patients with
impairment of consciousness, neurological deficits, or
seizures, underwent cranial computed tomography (CT)
before lumbar puncture.
Empiric antibiotic therapy was defined as any parent-
eral antibiotic capable of crossing the blood-brain bar-
rier, administered for the purpose of treating bacterial
meningitis [8]. In the case of Lm meningitis, intravenous
administration of penicillin, ampicillin, amoxicillin/cla-
vulanic acid, piperacillin/tazobactam, a carbapenem,
moxifloxacin or trimethoprim-sulfamethoxazole was
considered adequate empirical therapy. During the fol-
low up performance of a brain CT or the administration
of adjunctive therapy (corticosteroids and/or phenytoin)
were left for the physician in charge to decide.
All patients were followed up until death or hospital
discharge. At discharge, all patients underwent a neuro-
logical examination, and outcome was measured accord-
ing to the Glasgow Outcome Scale [13]. A score of 1 on
this scale indicates death; a score of 2, a vegetative state;
a score of 3, severe disability; a score of 4, moderate dis-
ability; and a score of 5, mild or no disability. A favour-
able outcome was defined as a score of 5, and an
unfavourable outcome was defined as a score of 1-4.
For the statistical analysis the SPSS 16.0 software
package was used. Univariate analysis of variables from
the entire population was performed using unpaired stu-
dent’s t-test for parametric continuous variables after
correction for equality of variance (Levene’s test), U
Mann-Whitney test for non parametric continuous vari-
ables, and Pearson’s chi-square test or Fisher’s exact test
for categorical variables. Statistical significance was con-
sidered when p <0.05. All p values were two-sided.
Furthermore, a multivariate using logistic regression
analysis was used to identify independent associations
with Lm meningitis with results presented as Odds-
Ratio (OR) and the 95% confidence intervals (95% CI).
Finally, a univariate analysis comparing immunocompro-
mised and immunocompetent patients with Lm menin-
gitis was performed as previously indicated.
Results
Two hundred and seventy-eight patients with Ac-ABM
were included in this prospective study. The most
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(Table 1). Forty-six episodes of Lm meningitis were
identified in 46 patients. Three patients were excluded
from the analysis because they were prematurely trans-
ferred to another hospital. Lm grew from the CSF in
40/43 (93%) cases and from blood culture in 27/43 (63%).
Table 2 shows the comparison between Lm meningitis
and episodes with other aetiologies. In this univariate
analysis those risk factors and clinical characteristics
showing differences at admission were: age, immunosu-
pression, previous otitis, focal neurological deficit, cere-
bellum dysfunction, WBC count CSF and percentage of
neutrophils, CSF/blood glucose ratio, and CSF protein
levels. However in the multiv a r i a t ea n a l y s i so n l ya g e
(OR 1.026; 95% CI 1.00-1.05; p = 0.042), immunosupres-
sion (OR 2.520; 95% CI 1.05-6.00; p = 0.037), and CSF/
blood glucose ratio (OR 39.42; 95% CI 4.01-387.50;
p = 0.002) were independently associated with Lm
meningitis.
All patients with acute community-acquired Lm
meningitis were immunocompromised or over 50 years
old. The baseline characteristics of these patients and
the differences between patients with and without
immunocompromise are shown in Table 3. The median
age was 69 ± 30 years and 24 of the 43 cases (56%)
were male. Twenty-nine (68%) patients were immuno-
compromised and fourteen (32%) were immunocompe-
tent patients. The nature of immunocompromise were:
Twelve (41%) patients were receiving immunosuppres-
sive therapy, 8 (27.5%) had haematological and solid
malignancy, 2 (6.8%) with connective tissue disease,
2 (6.8%) with end-stage renal disease and 5 (17.2%) with
HIV infection.
In our series, in patients with Lm meningitis, fever was
the most common symptom (91%). The majority of
patients also had altered mental status at presentation,
while headache was present in nearly half the patients.
The classic triad of fever, neck stiffness and altered
mental status was present in 21 (49%) patients; however,
almost all patients (95%) had at least 1 or more of these
symptoms. Thirty-two percent of the patients had focal
neurological findings at presentation, 12% presented
cerebellum dysfunction, and 9% had seizures. The most
frequent focal neurological finding was cranial nerve
palsies. The median duration of symptoms before
admission to the hospital was two days. Immunocom-
promised patients had a lower incidence of the classic
triad (45% vs. 71%; p = 0.039), headache (59% vs 85%;
p = 0.076), and focal neurological deficit at presentation
(28% vs 43%; p = 0.317) as compared with immunocom-
petent patients with acute community-acquired Lm
meningitis.
Thirty-nine (91%) patients underwent CT in the emer-
gency department. In 30 of 39 (77%), there were no
abnormalities associated with the listerial infection. In
the remaining 9 (23%) patients, the most common
findings were focal lesions and/or hydrocephalus.
All patients with hydrocephalus were treated
neurosurgically.
Lumbar puncture was performed in all patients. CSF
findings are outlined in Table 3. There was no relation
between low CSF leukocyte count and age or immuno-
compromise. The most frequently found serotype was
the 4b in 23 (82%) of 28 cases.
Empirical antimicrobial therapy was intravenous ampi-
cillin (2 g every four hours) for 34 (79%) of 43 patients,
in 11 (32%) of them combined with aminoglycosides.
The rest of six patients received trimethoprim-
sulfamethoxazole therapy in two cases and meropenem
in the other four cases as empirical antibiotic treatment.
Three patients that did not received appropiated empiri-
cal treatment receiving ceftriaxone plus vancomycin.
Twenty-one patients (49%) received adjunctive therapy
with dexamethasone; in 14 cases, the first dose was
given previously or concomitantly to the first antibiotic
dose, and eleven patients received phenytoin. There
were no major side-effects of dexamethasone therapy
(gastro-intestinal bleeding, hyperglycemia).
The overall mortality was 28% (12 of 43 patients) and
five of thirty-one (16.1%) surviving patients had a neuro-
logical deficit at discharge. Neurological abnormalities
identified were cranial nerve palsies in 2 (6.4%) and
hemiparesis in 3 (9.6%). No patients had hearing impair-
ment. Definitive ampicillin plus gentamicin therapy was
significantly associated with unfavourable outcome (67%
vs 28%; p = 0.024) and a higher mortality (67% vs 32%;
p = 0.040) due to Lm infection, Table 4.
Discussion
Early administration of adequate antimicrobial therapy is
the cornerstone of treatment in patients with meningitis.
Despite developments in antimicrobial agents, Lm
meningitis is still a serious disease that carries high
morbidity and mortality rates. A relevant aspect in this
study is the prospective inclusion of adult patients with
acute community-acquired Lm meningitis, to evaluate
Table 1 Aetiologies in 278 episodes of acute community-
acquired bacterial meningitis in adults
Organism n(%)
Streptococcus pneumoniae 135 (48.5)
Neisseria meningitidis 63 (22.6)
Listeria monocytogenes 46 (16.5)
Haemophilus influenzae 9 (3.2)
Escherichia coli 4 (1.4)
Streptococcus agalactiae 4 (1.4)
Others 17 (6.1)
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contribute to early appropriate antimicrobial therapy of
this serious and life-threatening disease. Thus, in a large
cohort of patients with Ac-ABM, our study reveals that
elderly, immunocompromised patients, and a higher
CSF/blood glucose ratio were independently associated
with isolation of Lm as the responsible pathogen.
In our own series, the incidence of acute community-
acquired Lm meningitis in adults was 16.5% (46/278).
Previously, in a multicenter study [14] conducted in the
United States, the authors reported that Lm accounted
for 8% of the cases of bacterial meningitis. Other studies
from Europe and North America have reported inci-
dences of 5%-10% or more among all episodes of
Ac-ABM among adults [15-18]. Over a 36-year period,
Durand et al. described that Lm accounted for 11% of
the episodes of Ac-ABM in adults [7]. The probable
increase in the incidence may be attributed to longer
life expectancy, changes in diet or food processing, and
the higher number and longer survival of immunocom-
promised people [2].
On the other hand, symptoms and signs of patients
presenting with Lm meningitis were not different from
those found in the general population of patients with
Ac-ABM, according to previous studies [19].
The CSF profile in patients with Listeria infection
revealed significantly fewer WBC and lower protein con-
centrations than patients with infection due to other
pathogens, and a trend towards less hypoglycorrhachia
and a lower percentage of PMNs. However, these find-
ings do not apply to all cases [20]. In the appropriate
clinical situation, clinicians should not exclude Lm based
on the degree of pleocytosis, the percentage of PMNs, or
the concentration of glucose or protein in the CSF.
The experience in the present series suggests that the
Gram stain is negative in two-thirds of the cases of Lm
meningitis, and may be misleading in many of the
remaining cases. Clinicians should be aware of these dif-
ficulties, inform the microbiology department when they
suspect this pathogen, and not rule out Lm based on
Gram stain alone. Furthermore, despite the diversity of
serotypes of Lm, only three serotypes are responsible for
>90% of human disease: 1/2a, 1/2b, and 4b. The major-
ity of strains were serotype 4b [21] (23 of 28 cases;
82%), suggesting that serotype 4b of Lm is more virulent
than others. Otherwise, blood cultures were positive in
more than half of the cases in the present series. Some
reports advocate the use of the polymerase chain reac-
tion or immunoassays for the early detection of Lm
[22,23], but these techniques need further evaluation.
Table 2 Comparison of episodes of acute community-acquired Lm meningitis versus other aetiologies
Listeria monocytogenes (n = 43) Other agents (n = 232) p
Age (median ± IQR) 69 ± 30 56 ± 33 0.019
Gender (male) 24 (56)
d 128 (55) 0.938
Immunocompromised 29 (67) 86 (37) <0.001
Previous otitis 1 (2.1) 43 (19.5) 0.005
Fever 39 (91) 186 (84) 0.246
Headache 29 (67) 166 (77) 0.146
Vomiting 20 (46) 132 (57) 0.070
Neck stiffness 30 (70) 167 (72) 0.204
Classic Triad
a 21 (49) 90 (39) 0.533
GCS
b at admission (median ± IQR) 13 ± 4 12 ± 4 0.664
Seizures 4 (9) 17 (7) 0.688
Focal neurological deficit 14 (32) 27 (12) 0.022
Cerebellum dysfunction 5 (12) 5 (2) <0.001
Hyponatremia 19 (44) 60 (26) 0.066
Duration of symptoms in hours (median ± IQR) 70 ± 53 48 ± 53 0.07
WBC count CSF
c (median ± IQR) 550 ± 2480 2860 ± 9380 0.007
CSF neutrophils ( median±IQR) 70 ± 59 90 ± 13 <0.001
CSF/blood glucose (median ± IQR) 0.26 ± 0.24 0.09 ± 0.26 <0.001
Protein level g/L ( median ± IQR) 2.0 ± 1.96 3.68 ± 5.53 <0.001
Mortality 12 (29) 36 (16) 0.059
a Triad of fever, neck stiffness and change in mental status.
b GCS: Glasgow Coma Scale.
c CSF: Cerebrospinal Fluid.
d Results are expressed as n (%) unless otherwise specified.
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Variable
a Patients Immunocompromised Immunocompetent p *
Number of patients 43 29 14
Age (median ± IQR) 69 ± 30 69.5 ± 32 64.5 ± 23 1
Elderly (60 years or older) 24 (56) 16 (55) 8 (58) 0.903
Antibiotic therapy before admission
b 3/43 (7) 2/29 (7) 1/14 (7) 0.950
Median time to admission (hours) 48.5 48 49 0.500
Time to admission > 48 h 22/43 (51) 15/29 (52) 7/14 (50) 0.916
Symptoms at presentation
Seizures 4/43 (9) 3/29 (10) 1/14 (7) 0.735
Headache 29/43 (67) 17/29 (59) 12/14 (85) 0.076
Vomiting 20/43 (46) 12/29 (41) 8/14 (57) 0.331
Neck stiffness 30/43 (70) 17/29 (62) 12/14 (86) 0.114
Temperature ≥ 38°C 39/43 (91) 26/29 (90) 13/14 (93) 0.735
Glasgow Coma Scale at admission (median ± IQR) 13 ± 3 13 ± 5 13 ± 1 0.279
Classic Triad
c 21/43 (49) 11/29 (45) 10/14 (71) 0.039
Focal neurological deficit
Any 14/43 (32) 8/29 (28) 6/14 (43) 0.317
Cranial nerve palsies 7/14 (50) 4/8 (50) 3/6 (50) 1
Large nerve palsies 2/14 (12) 2/8 (25) 0 0.186
Cerebellum dysfunction 5/14 (38) 2/8 (25) 3/6 (50) 0.334
Laboratory findings
Indexes of CSF
d inflammation
WBC count (median ± IQR) 550 ± 2400 936 ± 3610 310 ± 520 0.069
< 100 cells/mL 5/40 (12) 3/27 (11) 2/13 (15) 0.702
100-999 cells/mL 20/40 (50) 11/27 (40) 9/13 (70) 0.091
> 999 cells/mL 15/40 (37) 13/27 (49) 2/13 (15) 0.045
Protein level,g/L (median ± IQR) 2.4 ± 2.7 2.39 ± 2.26 2.88 ± 3.16 0.357
Protein level > 2 g/L 23/43 (53) 17/29 (67) 6/14 (32) 0.331
% PMN (median ± IQR) 70 ± 59 70 ± 62 65 ± 48 0.418
> 50% 27/40 (67) 19/27 (67) 8/13 (61) 0.576
CSF/blood glucose (median ± IQR) 0.26 ± 0.23 0.27 ± 0.25 0.22 ± 0.23 0.243
CSF Gram stain
Gram-positive rods 13/43 (30) 9/29 (31) 4/14 (29) 0.869
Positive CSF culture
e 40/43 (93) 26/29 (67) 14/14 0.212
4b serotype 23/28 (82) 12/16 (75) 11/12 (92) 0.355
1/2b serotype 5/28 (18) 4/16 (25) 1/12 (8) 0.254
Positive blood cultures 27/43 (63) 18/29 (62) 9/14 (63) 0.643
Blood analytical findings
WBC count (10
9/L, (median ± IQR) 12 ± 10 10 ± 11 15 ± 5 0.006
Platelets (10
9/L, median ± IQR) 182 ± 75 161 ± 87 193 ± 70 0.492
Sodium (mEq/L, median ± IQR) 135.1 ± 4.9 134.2 ± 5 136.9 ± 3.8 0.086
Hyponatremia 19/43 (44) 15/29 (51) 4/14 (28) 0.152
Outcome
Unfavorable outcome (GOS
f<4) 15/43 (35) 8/29 (27) 7/14 (50) 0.184
Mortality 12/43 (28) 7/29 (24) 5/14 (35) 0.482
a Results are expressed as n (%) unless otherwise specified.
b Use of at least two doses of an oral or parenteral antibiotic within one week of the onset of meningitis.
c Triad of fever, neck stiffness and change in mental status.
d CSF: Cerebrospinal Fluid.
e The serotype identification only was done in 28 patients.
f GOS: Glasgow Outcome Scale.
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empirical therapy, 40/43 (93%), in 11 of them associated
to aminoglycosides. Our study showed that a definitive
combined therapy with aminoglycosides was significantly
associated with an increasing trend for an unfavourable
outcome and mortality, which corresponds with a pre-
v i o u ss t u d y[ 2 4 ] .T h e s er e s u l t sc o u l db ee x p l a i n e db y
Lm meningitis patients have an associated co-morbid
condition, in which addition of an aminoglycoside may
be harmful. For this reason, actually this combined
therapy is been questioned, moreover of the drug’s asso-
ciated nephrotoxicity and inability to cross the blood-
brain barrier. In this way, every case should be
approached independently, although certain subsets of
patients probably require empiric antibiotic treatment
for Lm, such as patients over 45-50 years of age,
patients with immunosuppression, a higher CSF/blood
glucose ratio, or patients with a Gram stain of CSF
revealing Gram-positive bacilli [19], and the associated
with aminoglycosides should be avoid in order to
improve patient’s outcome.
As i g n i f i c a n tn u m b e ro fp a t i e n t s ,5o f3 1( 1 6 . 1 % )o f
the survivors in the present series had some degree of
residual neurological deficit at hospital discharge.
Although an even higher incidence of residual neurolo-
gical deficits (32%) was noted among survivors enrolled
in 3 previous series and deficits persisted for more
than a year in 4 of 10 of those cases with adequate fol-
low up [25-27].
Moreover, mortality due to Lm is among the highest
of all causes of acute bacterial meningitis [28]. Part of
the high mortality of Listeria infection may relate to the
increased number of immunocompromised and older
patients affected by this pathogen [29,30]. Although evi-
dence for use of anticonvulsant prophylaxis in Lm
meningitis is lacking, it may be considered as seizures
have previously been related to increases mortality [31],
as did we in the present series, although this was not
statistically significant. Further studies are needed in
order to clarify this point.
Finally, the role of adjunctive therapy with corticoster-
oids has been widely debated. A clinical trial showed a
beneficial effect of early dexamethasone treatment in
adults with bacterial meningitis [32]. Nevertheless, there
are no studies on the effect of dexamethasone in adult
Listeria meningitis. We observed a higher survival rate
among those patients that received dexamethasone con-
comitant to antibiotic, although this association did not
reach statistical significance. Our results suggest that
further studies are needed to evaluate the effect of corti-
costeroid therapy in adult patients with Lm meningitis.
The present study has several limitations. First, given
the small number of patients, we were unable to develop
a statistical model to identify risk factors independently
associated with a poor outcome or death in patients
with acute community-acquired Lm meningitis. Sec-
ondly, only patients who underwent lumbar puncture
and who had a positive cerebrospinal fluid culture were
Table 4 Description of patients with acute community-acquired Lm meningitis who survivied or died
Survivors n = 31 Non-Survivors n = 12 p
Age (median ± IQR) 67 ± 26 71 ± 43 0.999
Elderly patient 17 (55) 7 (58) 0.836
Immunocompromised 22 (71) 7 (58) 0.482
Neurological finding 9 (29) 2 (17) 0.698
GCS
b at presentation (median ± IQR) 13 ± 11 13 ± 8 0.453
Classic Triad
c 14 (45) 7 (58) 0.438
WBC > 999 cells/mL 10 (33) 5 (42) 0.282
Protein level g/L (median ± IQR) 2.08 ±1.3 2.1 ± 4.4 0.685
CSF
d/blood glucose ratio (median ± IQR) 0.27 ± 0.24 0.18 ± 0.21 0.448
Hyponatremia 13 (42) 6 (50) 0.633
Seizures 2 (7) 2 (17) 0.308
Empirical Ampicilllin + gentamicin therapy 8 (26) 3 (25) 0.957
Definitive Ampicillin + gentamicin therapy 10 (32) 8 (67) 0.040
Dexamethasone concomitant to antibiotic 17 (55) 4 (33) 0.206
Phenytoin 8 (26) 3 (25) 0.999
a Results are expressed as n (%) unless otherwise specified
b GCS: Glasgow Coma Scale.
c Triad of fever, neck stiffness and change in mental status.
d CSF: Cerebrospinal Fluid.
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20 percent of patients with acute community acquired
bacterial meningitis. Third, delay of antimicrobial ther-
apy was not recorded. Despite all these limitations, we
consider that this study contributes to our knowledge of
risk factors associated with development of acute com-
munity-acquired Lm meningitis, and to evaluating epide-
miology, clinical features, management, and outcome in
this homogenous population of adult patients with acute
community-acquired Lm meningitis.
Conclusions
To sum up, our study showed elderly or immunocom-
promised patients and a higher CSF/blood glucose ratio
in patients with Ac-ABM must alert clinicians about Lm
aetiology. Furthermore, we observed a high incidence of
acute community-acquired Lm meningitis in adults and
the addition of aminoglycosides to treatment should be
avoid in order to improve the patients’ outcome. Never-
theless, despite developments in intensive care and anti-
microbial therapy, this entity is still a serious disease
that carries high morbidity and mortality rates. Further
studies should focus on specific interventions (e.g. adju-
vant therapies) that could help to improve the poor
prognosis of these patients.
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